<DOC>
	<DOCNO>NCT01359696</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I , dose-escalation study ass safety , tolerability , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) GDC-0425 administer without gemcitabine .</brief_summary>
	<brief_title>A Study Evaluating Safety , Tolerability , Pharmacokinetics GDC-0425 Administered With Without Gemcitabine Patients With Refractory Solid Tumors Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Age &gt; = 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Signed Informed Consent Form Histologically cytologically document , locally advanced metastatic solid tumor lymphoma standard therapy either exist proven ineffective intolerable Adequate hematologic endorgan ( liver kidney ) function For female patient childbearing potential male patient partner childbearing potential , agreement patient patient and/or partner use effective form contraception Patients enrol certain phase must willing provide fresh and/or archival tumor sample History prior significant toxicity class agent GDC0425 gemcitabine require discontinuation treatment Allergy , hypersensitivity contraindication GDC0425 formulation gemcitabine Experimental therapy anticancer therapy within 4 week prior first dose study drug treatment Radiotherapy within 2 week prior first dose study drug treatment More two regimen cytotoxic chemotherapy treatment locally advance metastatic cancer History receive highdose chemotherapy require bone marrow stem cell support History receiving radiation 25 % bone marrowbearing area Acute drugrelated toxicity previous therapy resolve prior study entry , except alopecia mild neuropathy Current severe , uncontrolled systemic disease ( include limit clinically significant cardiovascular , pulmonary , renal disease ongoing active infection ) exclude cancer Significant heart disease heart dysfunction include limited uncontrolled severe hypertension , heart failure , reduce cardiac contractility Uncontrolled ascites , due disease cancer Inability unwillingness swallow pills/capsules History malabsorption condition would interfere drug absorption Any history active stomach and/or intestine bleed within 6 month prior screen Known HIV infection Pregnancy , lactation , breastfeed Known brain metastasis untreated , symptomatic , require therapy control symptoms Inability comply study follow procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>solid cancer</keyword>
</DOC>